C-SSKLRejuvenate Bio
gene therapy, FGF21, partial reprogramming
reprogramminggene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-SSKL
C-SSKLC-SSKLgene therapy, FGF21, partial reprogramming
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Rejuvenate Bio gene therapy, FGF21, partial reprogramming
Rejuvenate Bio is developing novel therapies to treat aging and age-related diseases through targeted gene therapies. The company launched out of George Church's lab at Harvard Medical School and the Wyss Institute. Its site describes work in human and animal health, including liver-directed gene therapy, FGF21, cardiac and metabolic disease, and canine age-related conditions.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Rejuvenate Bio — Early mechanism · Lower middle. Derived deterministically from 22 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (15 programs at preclinical).…
Source: Deterministic